445480-33-1

Basic information

• Product Name: threo-Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1,1-
• Synonyms: threo-Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1,1-
• CAS NO: 445480-33-1
• Molecular Formula: C10H19NO4
• Molecular Weight: 217.26216
• Product Categories: N-BOC
• Mol File: 445480-33-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: threo-Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1,1-(CAS DataBase Reference)
• NIST Chemistry Reference: threo-Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1,1-(445480-33-1)
• EPA Substance Registry System: threo-Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1,1-(445480-33-1)

Safety Data

• Hazardous Substances Data: 445480-33-1(Hazardous Substances Data)

Upstream product

• 286-22-6 3,4-epoxytetrahydropyran 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1096770-58-9 (3R,4S)-4-aminotetrahydro-2H-pyran-3-ol 

Downstream Products

• 477584-42-2 tert-butyl [(4S)-3-oxotetrahydro-2H-pyran-4-yl]carbamate 
• 477584-42-2 tert-butyl (3-oxotetrahydro-2 H-pyran-4-yl)carbamate 

Relevant articles and documents

CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES

The present invention provides novel cyclic substituted imidazo[4,5- c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.